Big Pharma Leaders Show United Front On COVID-19
Lilly CEO Warns Against Trump-Style Unilateralism
Costs will be an issue, but not today; industry and healthcare systems are working at breakneck speed to catch up with the deadly virus.
You may also be interested in...
The Stockholm-headquartered company has exceeded expectations with its IPO, and now faces the ‘big reveal’ for its lead asset Nefecon.
Pharma is looking to GAVI to oversee a fair distribution and avoid ‘vaccine nationalism’ – but countries can still sign bilateral deals with companies.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.